Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTMVYH)

Drug Name
ZM-39923 Drug Info
Synonyms
ZM39923; 273727-89-2; ZM-39923; UNII-M0ZX82000S; M0ZX82000S; 3-[benzyl(propan-2-yl)amino]-1-(naphthalen-2-yl)propan-1-one; 3-(Benzyl(propan-2-yl)amino)-1-(naphthalen-2-yl)propan-1-one; JSASWRWALCMOQP-UHFFFAOYSA-N; Tocris-1367; NCGC00025126-01; AC1L1GQH; Lopac-Z-4626; Lopac0_000844; SCHEMBL2891331; GTPL5994; CHEMBL596674; CHEBI:92715; BDBM81346; CTK6A9359; M9440 (Me-3,4-dephostatin); ZINC1487934; HY-12589A; HSCI1_000104; AKOS030526763; CS-4952; CCG-204927; NCGC00025126-02; NCGC00016107-05; NCGC00016107-02; NCGC00016107-09
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
3797
ChEBI ID
CHEBI:92715
CAS Number
CAS 273727-89-2
TTD Drug ID
DMTMVYH

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Janus kinase 3 (JAK-3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tofacitinib DMBS370 Rheumatoid arthritis FA20 Approved [2]
Ritlecitinib DMYKNME Alopecia areata ED70.2 Approved [3]
ASP-015K DMZ1UOI Psoriasis vulgaris EA90 Phase 3 [4]
VX-509 DM2U3MX Rheumatoid arthritis FA20 Phase 2/3 [5]
Cerdulatinib DMSCR2H B-cell lymphoma 2A86 Phase 2 [3]
ATI-501 DMTY6OF Alopecia ED70 Phase 2 [6]
ATI-502 DM8NODR Alopecia ED70 Phase 2 [7]
TD-8236 DMTOMJN Asthma CA23 Phase 2 [8]
ALXN2075 DM1BSD8 Non-hodgkin lymphoma 2B33.5 Phase 1/2 [9]
SNA-125 DM8L1GJ Atopic dermatitis EA80 Phase 1 [3]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Janus kinase 1 (JAK-1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Baricitinib DM4ONW5 Rheumatoid arthritis FA20 Approved [5]
Ruxolitinib DM7Q98D Essential thrombocythemia 3B63.1Z Approved [10]
Upadacitinib DM32B5U Rheumatoid arthritis FA20 Approved [11]
ASP-015K DMZ1UOI Psoriasis vulgaris EA90 Phase 3 [12]
SHR0302 DMUL8ZT Ulcerative colitis DD71 Phase 3 [13]
Cerdulatinib DMSCR2H B-cell lymphoma 2A86 Phase 2 [3]
CTP-543 DM3SYOK Alopecia ED70 Phase 2 [14]
INCB039110 DMD9RV3 Malignant neoplasm 2A00-2F9Z Phase 2 [12]
PF-06700841 DMMGSFV Asthma CA23 Phase 2 [3]
ATI-501 DMTY6OF Alopecia ED70 Phase 2 [6]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Janus kinase 1 (JAK-1) TT6DM01 JAK1_HUMAN Inhibitor [1]
Janus kinase 3 (JAK-3) TTT7PJU JAK3_HUMAN Inhibitor [1]

References

1 Naphthyl ketones: a new class of Janus kinase 3 inhibitors. Bioorg Med Chem Lett. 2000 Mar 20;10(6):575-9.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049).
5 Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
6 Clinical pipeline report, company report or official report of Aclaris Therapeutics.
7 ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health.
8 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
9 The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 1;23(9):2313-2324.
10 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2047).
13 Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial. Am J Clin Dermatol. 2021 Nov;22(6):877-889.
14 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)